Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics
Status:
Withdrawn
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this investigation is to compare subjects at high risk for silent myocardial
ischemia in the placebo group to subjects at high risk for silent myocardial ischemia in the
ranolazine group to determine if ranolazine can be used as a treatment to decrease silent
myocardial ischemia (SMI). Subjects at high risk for silent myocardial ischemia are defined
in this protocol as diabetics with stable ischemic heart disease. This study will look at the
impact ranolazine treatment has on biomarkers that have been shown to be highly associated
with increased risk of morbidity and mortality in relation to SMI. If the hypothesis is
correct, further studies can be conducted to determine if treatment with ranolazine has
impact on long-term outcomes such as hospitalizations, myocardial infarction, congestive
heart failure or sudden cardiac death.